# Safety and Efficacy of Seroquel in First Episode Schizophrenia

> **NCT00254241** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 80 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Seroquel and Risperidone

## Key facts

- **NCT ID:** NCT00254241
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 80 (—)
- **Last updated:** 2009-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254241, "Safety and Efficacy of Seroquel in First Episode Schizophrenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00254241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*